Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
Intervenn Biosciences, a US-based precision medicine technology developer co-founded by Stanford University and University of California, Berkeley faculty, has closed a $201m series C round.
The round was co-led by telecoms firm SoftBank, health system Heritage Provider Network, Irving Investors and Highside Capital Management. It was filled out by Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
Intervenn Biosciences has developed an artificial intelligence-equipped glycoproteomics platform and a liquid biopsy assay for immune checkpoint inhibitor response prediction. It will use the series C funding to accelerate technology development and commercialisation efforts.
Intervenn’s co-founders include faculty from two institutions – Stanford University’s Carolyn Bertozzi and University of California, Berkeley’s Carlito Lebrilla.
Aldo Carrascoso, co-founder and chief executive of Intervenn Biosciences, said: “We are thrilled to have such strong support from this global investor group to support the next phase of our evolution.
“Our new investors,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
